Tag: TrovaGene Inc

Finance

Healthcare Decliners: Aldeyra Therapeutics (NASDAQ:ALDX), Ignyta (NASDAQ:RXDX), Vital Therapies (NASDAQ:VTL), Actinium (NYSEMKT:ATNM), TrovaGene (NASDAQ:TROV)

Aldeyra Therapeutics Inc (NASDAQ:ALDX) quiet period is set to expire on Wednesday, June 11th. Aldeyra Therapeutics had issued 1,500,000 shares in its IPO on May 2nd, AR Network reports. The total size of the offering was $12,000,000 based on an initial share price of $8.00. Aldeyra Therapeutics Inc (NASDAQ:ALDX) stock performance was -7.08% in last session and finished the day at $6.69. Traded volume was … Continue reading Healthcare Decliners: Aldeyra Therapeutics (NASDAQ:ALDX), Ignyta (NASDAQ:RXDX), Vital Therapies (NASDAQ:VTL), Actinium (NYSEMKT:ATNM), TrovaGene (NASDAQ:TROV)

Jayne Crisman
FB Nasdaq FB Facebook
Finance

Biotech Bullish Stocks: TrovaGene Inc (NASDAQ:TROV), Vital Therapies (NASDAQ:VTL), RXi Pharmaceuticals (NASDAQ:RXII), Applied Genetic Technologies Corp (NASDAQ:AGTC), IGI Laboratories (NYSEMKT:IG)

TrovaGene Inc (NASDAQ:TROV) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at TROV given that, according to its RSI reading of 24.68, it is now in oversold territory. TrovaGene Inc (NASDAQ:TROV) stock performance was 8.73% in last session … Continue reading Biotech Bullish Stocks: TrovaGene Inc (NASDAQ:TROV), Vital Therapies (NASDAQ:VTL), RXi Pharmaceuticals (NASDAQ:RXII), Applied Genetic Technologies Corp (NASDAQ:AGTC), IGI Laboratories (NYSEMKT:IG)

Mark DeFrance
Finance

New Lows: ArQule, Inc. (NASDAQ:ARQL), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), TrovaGene Inc (NASDAQ:TROV)

ArQule, Inc (NASDAQ:ARQL) CEO Paolo Pucci purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, May 20th. The stock was purchased at an average cost of $1.42 per share, with a total value of $7,100.00. Following the transaction, the chief executive officer now directly owns 232,280 shares of the company’s stock, valued at approximately $329,838. ArQule, Inc. (NASDAQ:ARQL) stock performance was -2.76% … Continue reading New Lows: ArQule, Inc. (NASDAQ:ARQL), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), TrovaGene Inc (NASDAQ:TROV)

Mark Doerr